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Background: Efforts to improve the outcome of liver surgery by combining curative resection with chemotherapy
have failed to demonstrate definite overall survival benefit. This may partly be due to the fact that these studies
often involve strict inclusion criteria. Consequently, patients with a high risk profile as characterized by Fong’s
Clinical Risk Score (CRS) are often underrepresented in these studies. Conceptually, this group of patients might
benefit the most from chemotherapy. The present study evaluates the impact of neo-adjuvant chemotherapy in
high-risk patients with primary resectable colorectal liver metastases, without extrahepatic disease. Our hypothesis is
that adding neo-adjuvant chemotherapy to surgery will provide an improvement in overall survival (OS) in patients
with a high-risk profile.
Methods/Design: CHARISMA is a multicenter, randomized, phase III clinical trial. Patients will be randomized to
either surgery alone (standard treatment, arm A) or to 6 cycles of neo-adjuvant oxaliplatin-based chemotherapy,
followed by surgery (arm B). Patients must be ≥ 18 years of age with liver metastases of histologically confirmed
primary colorectal carcinoma. Patients with extrahepatic metastases are excluded. Liver metastases must be deemed
primarily resectable. Only patients with a CRS of 3–5 are eligible. The primary study endpoint is OS. Secondary
endpoints are progression free survival (PFS), quality of life, morbidity of resection, treatment response on neo-adjuvant
chemotherapy, and whether CEA levels can predict treatment response.
Discussion: CHARISMA is a multicenter, randomized, phase III clinical trial that will provide an answer to the
question if adding neo-adjuvant chemotherapy to surgery will improve OS in a well-defined high-risk patient
group with colorectal liver metastases.
Trial registration: The CHARISMA is registered at European Union Clinical Trials Register (EudraCT), number:
2013-004952-39, and in the “Netherlands national Trial Register (NTR), number: 4893.
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Colorectal liver metastases: surgical treatment
Colorectal cancer (CRC) is one of the leading causes of
cancer death. It is in the top 3 most commonly diag-
nosed cancers, with over 1.2 million new cases and over
600,000 deaths estimated to have occurred in 2008
worldwide [1]. In approximately 20% of patients distant
metastases are present at time of diagnosis [2]. The liver
is the most common metastatic site. Approximately 50%
of patients with early-stage disease will eventually de-
velop colorectal liver metastases (CRLM) [3,4].
When metastases of CRC patients are restricted to the
liver, possible curative treatment can be obtained by sur-
gical resection. Complete surgical resection of CRLM
improves 5-year survival rates to around 35-60% in se-
lected patients [5-8]. However in only 10-20% of patients
surgical resection of CRLM is feasible. Although surgery
for CRLM provides the only potential for cure, cancer
relapse is a common phenomenon, with a recurrence
rate of up to 50% in the first 2 years after surgery [9].
Chemotherapy for colorectal liver metastases
Initially, systemic treatment with 5-fluoruracil based reg-
imens was standard of care in CRLM, improving OS
from 6 to 10–12 months. The development of chemo-
therapeutic agents such as oxaliplatin and irinotecan has
subsequently improved OS to a median of up to 24
months. Sequential treatment with all available cytotoxic
agents, as well as the introduction of Epidermal Growth
Factor receptor (EGFR) and Vascular Endothelial
Growth Factor (VEGF) binding monoclonal antibodies
have further increased overall survival [10-13].
The high relapse rate after curative resection of
CRLM, and the efficacy of modern systemic treatment
in the metastatic setting, have prompted investigators to
perform numerous studies to evaluate the potential role
of systemic chemotherapy combined with liver resection.
The purpose of both adjuvant and neo-adjuvant chemo-
therapy is to treat microscopic disease that is not ad-
dressed by surgery. This microscopic disease may be
promoting the high relapse rate that is observed after
liver surgery [9]. Notably, current literature suggests
that timing of additional chemotherapy (adjuvant vs.
neo-adjuvant) seems to have no influence on outcome
[14]. The role of perioperative chemotherapy in case of
resectable CRLM was established in a randomized con-
trolled trial [15]. In the mature OS analysis of this trial
there was no significant effect on OS after a median
follow up of 7 years [16].
Stratification by clinical risk score
In the past, several clinical risk scores for the outcome
of patients with CRLM have been published [7,17-25]. In
1999, Fong et al. described the most widely used CRS[19]. This prognostic scoring system has been verified by
independent investigators [26]. Several authors have pro-
posed the concept of stratification by CRS in relation to
the effects of a multimodal treatment strategy on OS.
These authors suggest that patients with a high risk
score have a worse prognosis and might therefore bene-
fit more from chemotherapy compared to patients with
a low risk score [27-29].
These findings have prompted others and ourselves to
retrospectively evaluate data on patients who have
undergone liver resection for CRLM in the last decade
with and without chemotherapy, stratified by CRS ac-
cording to the Fong-criteria [30,31].
As described earlier, efforts to improve outcome of
liver surgery by combining the resection with chemo-
therapy have failed to demonstrate definite OS benefit.
This may partly be due to the fact that these studies
often involve strict study protocol inclusion criteria.
Consequently, patients with a high clinical risk score -
which might benefit the most from chemotherapy - are
often underrepresented in these studies. Since genuine
survival benefit has not yet been demonstrated, could
this low impact of chemotherapy on survival then be ex-
plained by the relatively low risk profile of the patients
included in these trials?Study aim and hypothesis
The CHARISMA randomized clinical trial will evaluate
the effect on OS of neo-adjuvant chemotherapy in pa-
tients with primary resectable CRLM and a CRS (Fong)
of 3–5, thereby bearing a poor prognosis. The primary
aim of this study is to compare OS in patients with re-
sectable liver metastases randomized for treatment with
chemotherapy, consisting of capecitabine and oxaliplatin
(XELOX), followed by surgery versus surgery alone.
We hypothesize that neo-adjuvant chemotherapy will
provide an improvement in OS in this high-risk patient
group. Secondary endpoints in this study will be pro-
gression free survival (PFS), quality of life as assessed by
QLQ-30 and MFI questionnaires, response to chemo-
therapy, morbidity of surgery and resection rate, and
whether carcinoembryonic antigen (CEA) can predict
for treatment response, PFS, and OS.Methods/Design
Patients with CRLM and a high CRS will be evaluated for
inclusion by the local multidisciplinary team meeting. In
this meeting, at least two surgeons with expertise in liver
surgery should be present. In case of doubt, the imaging
can be sent to a central expert panel. Patients are eligible
for randomization if, in the opinion of a local expert panel,
radical resection of the CRLM (R0-resection) is feasible.
Patients will be randomized 1:1 to either (Figure 1):
Figure 1 Study flowchart.
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Surgery of the liver metastases
 Arm B:
Neo-adjuvant oxaliplatin-based chemotherapy
followed by surgery of the liver metastases
Study population
Inclusion criteria
Age ≥ 18 years, ECOG performance status 0–1. Histologi-
cally confirmed primary colorectal carcinoma. Radio-
logical confirmed and primary resectable CRLM. CRS of
3–5 (Fong). Adequate bone marrow, liver and renal
functions.
Before any study related procedure will be pursued,
written informed consent must be given according to
ICH/GCP and national/local regulations.
Exclusion criteria
Adjuvant chemotherapy for colorectal carcinoma given < 6
months prior to detection of the liver metastases. Prior
non colorectal malignancies, except for basal or squamous
cell carcinoma of the skin, or patients with carcinoma in
situ of the cervix. Extrahepatic colorectal metastases.Locally advanced rectal cancer in situ requiring long-
course pre-operative chemoradiotherapy. Major surgical
procedures < 4 weeks prior to randomization. Pregnancy.
History of psychiatric disability. Clinically significant car-
diovascular disease. Uncontrolled hypertension. Lack of
physical integrity of the upper gastro-intestinal tract, mal-
absorption syndrome, or inability to take oral medication.
Known peripheral neuropathy. Organ allografts requiring
immunosuppressive therapy. Serious, non-healing wound,
ulcer, or bone fracture. Current or recent use of full-dose
oral anticoagulants or thrombolytic agents for therapeutic
purposes. Chronic treatment with corticosteroids. Serious
intercurrent infections. Current or recent treatment with
another investigational drug or participation in another
investigational study. Psychological, familial, sociological
or geographical conditions hampering compliance to the
study protocol and follow-up schedule.Assessment of operability
All patients have to be screened by their treating surgeon
for fitness to undergo liver surgery. In case of doubt, formal
anesthetic assessment is mandatory prior to randomization.
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Prior to resection of the CRLM, an expert panel must
review imaging of patients enrolled in this study in order
to determine resectability. Resectability is defined as the
possibility to achieve R0 resection. The liver remnant
should comprise a portal vein, a hepatic artery, and a
bile duct, one of the three main hepatic veins. The liver
remnant should have sufficient liver function and 2 seg-
ments free of metastases at the time of resection.
If these prerequisites cannot be met, radiofrequency
ablation (RFA) is allowed to obtain resectability. How-
ever, RFA may only be used in combination with liver
resection if the number of lesions to be treated with
RFA does not exceed 3 and the largest diameter of these
lesions is less than 3 cm.
Therapeutic regimen of patients Arm A
Patients should preferably be randomized within 2 weeks
of the definitive diagnosis of CRLM. Patients allocated
to Arm A should preferably have their surgery within 4
weeks after randomization and within 6 weeks after the
last CT scan. Adjuvant chemotherapy after R0 resection
is not allowed. Protocol therapy ends following the liver
resection.
Therapeutic regimen of patients Arm B
Patients in Arm B will receive 6 cycles of XELOX. Oxali-
platin will be administered in a 130 mg/m2 dose, Cape-
citabine in a 1000 mg/m2 dose. Patients should
preferably be randomized within 2 weeks of the defini-
tive diagnosis of CRLM. Patients allocated to Arm B
should start neo-adjuvant chemotherapy preferably
within 2 weeks after randomization and within 4 weeks
after the last CT scan. Treatment evaluation will occur
after the 3rd and 6th chemotherapy cycle. In the case of
progressive disease (PD) after the 3rd cycle, a resectabil-
ity check will take place. If patients remained resectable,
they will be planned for surgery within 4–6 weeks after
completion of the 4th cycle. If patients are assessed to be
irresectable, they will go off study protocol, but will be
analyzed according to intention to treat principle.
After the last day of chemotherapy exposure, resection
should take place at least 4 weeks, but at maximum 6
weeks later. Treatment evaluation can take place accord-
ing to local hospital procedures, but should at least con-
sist of a CT scan of the thorax/abdomen and CEA level.
Adjuvant chemotherapy after R0 resection is not




Primary endpoint of the study will be OS, calculated
from the date of randomization to the date of death ofthe patient, from any cause. Patients still alive at the date
of last contact will be censored.
Secondary endpoints
PFS will be defined from the date of randomization to the
first event defined as local/distant recurrence or progres-
sion or death from any cause.Criteria of evaluation
Progressive or recurrent disease can be detected by im-
aging modalities (e.g. CT scan). A rise in serum tumor
marker (e.g. CEA) is insufficient. In case of doubt, histo-
logical biopsy can provide definitive proof of progression/
recurrence. Response to neo-adjuvant chemotherapy will
be evaluated by CT scan using RECIST 1.1 criteria [32].
To evaluate the well-being of patients the European
Organization for Research and Treatment of Cancer Qual-
ity of Life questionnaire (EORTC QoL) will be used. The
EORTC QLQ-C30 is generally used to assess QoL of can-
cer patients; additionally the Multifactorial Fatigue Index
(MFI) will be used. Toxicity will be graded according to
the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0. Surgical complications will be de-
fined according to the standard classification of surgical
complications [33]. Postoperative mortality will be defined
as any death during hospitalization or within 30 days from
surgery. Complication and post-operative mortality rates
will be securely monitored and documented.
Statistical considerations
Sample size and accrual
On the basis of retrospective data, we expect the hazard
ratio (HR) for arm B to be 0.60. For the detection of a
HR of 0.60 for the chemotherapy arm and with an ex-
pected 5-year OS of 25% in arm A, with two-sided sig-
nificance level α = 0.05 and power 1 - β = 0.8, 126
deaths have to be reported before the final analysis will
take place. This number of events is expected to be
reached after the recruitment of 224 patients with an
average accrual rate of 56 patients per year, and an add-
itional follow up of 2 years. A HR = 0.60 corresponds to
an increase of 5-year OS of 43% in arm B.
Randomization
Eligible patients should be registered after written in-
formed consent and before start of treatment (based on
inclusion/exclusion criteria). Patients will be randomized
for surgery versus neo-adjuvant chemotherapy followed
by surgery in a 1:1 design. During randomization pa-
tients will be stratified by center, CRS score and status
of primary tumor (still in situ vs. resected) with a
minimization procedure, ensuring balance within each
stratum and overall balance.
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The main analysis addressing the primary endpoint is
planned after 126 events. No interim analysis is planned.
Ethics
The study has ethical approval from the Erasmus MC
medical-ethical committee. The study will be con-
ducted in accordance with the ethical principles of the
Declaration of Helsinki, the ICH-GCP Guidelines, the
EU Clinical Trial Directive (2001/20/EG), and applic-
able regulatory requirements. The local investigator is
responsible for the proper conduct of the study at the
study site.
Discussion
Currently, multimodal treatment is not incorporated in
the standard of care for primary resectable colorectal
liver metastases. To date, no definite evidence exists fa-
voring administration of (neo) adjuvant chemotherapy in
CRLM in addition to surgery. Considering the retro-
spective observations that pre-selection of patients by
clinical prognostic characteristics may define a patient
population expected to benefit from chemotherapy, CRS
stratification provides the base for this randomized con-
trolled trial.
Preceding studies of peri-operative chemotherapy
combined with liver surgery often engaged strict study
protocol inclusion criteria. Consequently, patients with a
high CRS - which might benefit the most from chemo-
therapy - are often underrepresented in these studies.
Possibly, this low impact of chemotherapy on survival
could be explained by the relatively low risk profile of
the patients included in these trials. Recently, two re-
ports on patients with relatively low risk for recurrence
have been published. Adam et al. performed an analysis
of the LiverMetSurvey database on patients with solitary,
metachronous, primarily resectable metastases. These
patients have particularly favorable tumor biology and a
low CRS. The authors concluded that these patients do
not benefit from preoperative chemotherapy [34]. A recent
systematic review of the literature by Lehmann et al.
concludes that routine use of neo-adjuvant chemother-
apy for patients with clearly resectable lesions limited
to the liver is not recommended due to a lack of benefit
on survival [35].
As mentioned before, several authors have proposed
the concept of stratification by CRS with regard to the
effects of systemic therapy. Tomlinson et al. demon-
strated on actual 10-year survivors of liver surgery for
CRLM that patients with a low CRS had a cure rate of
21% and that patients with a high CRS had a cure rate
of 10% [27]. They suggest that this finding may be used
to identify patients who might benefit from neo-
adjuvant chemotherapy [27]. In a large, non-randomizedstudy by Parks et al., adjuvant therapy did seem to im-
prove OS [28]. In this study, patients with a high CRS
had more benefit from adjuvant therapy than patients
with a low CRS, again suggesting a role for CRS when
considering chemotherapy.
These reports have stimulated others and our own
unit to retrospectively evaluate data on patients that
underwent liver resection for CRLM in the last decade
with and without chemotherapy, stratified by CRS ac-
cording to the Fong-criteria [19]. Rahbari et al. have
evaluated the role of adjuvant chemotherapy in a cohort
of 316 patients, of whom 43% were high-risk according
to the “Memorial Sloan-Kettering Cancer Center CRS”
(CRS > 2). They found that adjuvant chemotherapy had
a profound impact on OS in the high-risk population
(HR = 0.40), whereas in low-risk patients HR = 0.90
[31]. In a recent manuscript by Hirokawa et al. similar
results are described with de use of adjuvant chemother-
apy [36]. In our population of patients that underwent
resection for CRLM in Rotterdam (N = 365), we have
focused on neo-adjuvant chemotherapy. In this study, a
pronounced improvement in OS was found in high-risk
patients receiving neo-adjuvant chemotherapy versus no
chemotherapy (median 67 months vs. 33 months, HR =
0.55 [95% CI 0.35-0.84], p = 0.006). This difference was
absent in the low-risk group (median 65 months vs. 56
months, HR = 0.89 [95% CI 0.57-1.40], p = 0.62) [30].
Notably, these studies were retrospective and non-
randomized. The sample size calculation of the present
study is based on these retrospective data.
In a recent editorial by Jarnagin et al. it is suggested
that future trials should strongly consider stratification
by some scoring system [29], given the results of the
retrospective studies as mentioned above. Our study will
evaluate patients with resectable CRLM without extra
hepatic disease and a CRS of 3–5 thereby bearing a poor
prognosis. The primary aim of this study is to compare
OS rates of patients with resectable liver metastases ran-
domized for treatment with chemotherapy consisting of
capecitabine and oxaliplatin (XELOX) followed by sur-
gery, versus surgery alone. We hypothesize that adding
neo-adjuvant chemotherapy to surgical resection of
CRLM will provide an improvement in OS in patients
with a high-risk profile. As secondary objectives we will
study PFS, quality of life, treatment response on neoad-
juvant chemotherapy, morbidity of surgery and resection
rate, and whether CEA can predict for treatment re-
sponse, PFS, and OS.Abbreviations
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